2020
Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review.
Artukoglu BB, Li F, Szejko N, Bloch MH. Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32459404, DOI: 10.4088/jcp.19r12798.Peer-Reviewed Original ResearchConceptsTreatment of TDGreater score reductionPlacebo-controlled trialTardive dyskinesiaVitamin EPharmacologic treatmentTD symptomsScore reductionSystematic reviewPublication biasVesicular monoamine transporter 2 (VMAT2) inhibitorTardive dyskinesia treatmentVitamin E studiesTransporter 2 inhibitorsCalcium channel blockersDuration of treatmentTardive dyskinesia symptomsGreater reductionFixed-effects modelMedication classesHead trialsDyskinesia symptomsPrimary outcomePharmacologic agentsVMAT2 inhibitorsMeta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders
Zhou MS, Nasir M, Farhat LC, Kook M, Artukoglu BB, Bloch MH. Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2020, 60: 35-45. PMID: 32387445, DOI: 10.1016/j.jaac.2020.03.007.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPlacebo-controlled trialPharmacological treatmentPharmacological agentsAvailable pharmacological agentsAutism spectrum disorderSerotonin reuptake inhibitorsStandardized mean differenceStandardized study designsTreatment of ASDPharmacologic treatmentPrimary outcomeReuptake inhibitorsAntipsychotic medicationSpecific assessment toolsFolinic acidSpectrum disorderModest benefitRepetitive behaviorsMean differenceStudy designSmall effect sizesIndividual studiesTrialsPlacebo
2018
A Systematic Review of Pharmacologic Treatments for School Refusal Behavior
Tobon A, Reed MO, Taylor JH, Bloch MH. A Systematic Review of Pharmacologic Treatments for School Refusal Behavior. Journal Of Child And Adolescent Psychopharmacology 2018, 28: 368-378. PMID: 29741917, PMCID: PMC6909768, DOI: 10.1089/cap.2017.0160.Peer-Reviewed Original ResearchConceptsSchool refusalSystematic reviewPharmacologic treatmentFuture pharmacologic studiesSpecific psychosocial treatmentsLong-term outcomesNew pharmacologic agentsImportant pediatric problemSchool refusal behaviorComprehensive literature searchSignificant methodological limitationsImportant functional outcomesSecondary outcomesFunctional outcomeNewer antidepressantsPharmacologic trialsPharmacological treatmentPharmacologic agentsPharmacological interventionsPsychological interventionsPharmacologic studiesPsychosocial treatmentsMost trialsPediatric problemAnxiety symptoms
2016
Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. The Journal Of Clinical Psychiatry 2016, 77: e605-11. PMID: 27249090, DOI: 10.4088/jcp.14r09758.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsYale-Brown Obsessive Compulsive ScalePlacebo-controlled trialSerotonin reuptake inhibitorsTreatment of adultsObsessive-compulsive disorderSSRI responseSSRI treatmentReuptake inhibitorsSymptom improvementEfficacy of SSRIsTrials of SSRIsFirst-line pharmacologic treatmentCochrane Central RegisterStart of treatmentMajor depressive disorderEffect of doseObsessive Compulsive ScaleSSRI actionCentral RegisterPharmacologic treatmentPrimary outcomeControlled TrialsSSRI trialDepressive disorder
2012
Pharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias
Carrasco M, Volkmar FR, Bloch MH. Pharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias. Pediatrics 2012, 129: e1301-e1310. PMID: 22529279, PMCID: PMC3340598, DOI: 10.1542/peds.2011-3285.Peer-Reviewed Original ResearchConceptsSerotonin receptor inhibitorsPublication biasTrial resultsPlacebo-controlled trialAutism spectrum disorderRepetitive behaviorsAvailable medicationsPatient agePharmacologic treatmentPrimary outcomeUnpublished trialsEgger's testReceptor inhibitorsMean improvementSpectrum disorderFunnel plotTrial designSecondary analysisTrial durationRating ScaleEfficacyTrialsTweedie's trimMedicationsTreatment
2005
Clinical treatment of obsessive compulsive disorder.
Pittenger C, Kelmendi B, Bloch M, Krystal JH, Coric V. Clinical treatment of obsessive compulsive disorder. Innov Clin Neurosci 2005, 2: 34-43. PMID: 21120095, PMCID: PMC2993523.Peer-Reviewed Original ResearchObsessive-compulsive disorderSRI-resistant obsessive compulsive disorderMainstay of treatmentSerotonin reuptake inhibitorsEffective treatment modalityUse of clomipramineCurrent treatment strategiesRecent epidemiological studiesCommon psychiatric disordersCompulsive disorderCognitive behavioral therapyInvasive neurosurgical proceduresPartial responseAvailable medicationsPharmacologic treatmentReuptake inhibitorsTreatment armamentariumSignificant morbidityTreatment modalitiesChronic disordersMedication managementTreatment strategiesEpidemiological studiesPsychiatric disordersClinical treatment